# Shanghai Topgen Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-topgen-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.topgen.com.cn
- Total disclosed funding: $32M
- Latest round: Series D (Jun 2, 2022)
- Investors on record: 4

## About

Based in Shanghai, China, and established in 2012, Shanghai Topgen Pharmaceuticals operates as a biotechnology company that focuses on gene diagnosis, molecular science, cellular immunotherapy, and biopharmaceuticals mainly for the treatment of cancer. It has established branch sales offices in Zhejiang, Chongqing, Shandong, Jiangsu, Hubei, Henan, and Inner Mongolia. It has more than 800 cooperative hospitals and more than 40 medical laboratories. In January 2019, the company reached strategic cooperation with Illumina. In June 2018, it signed a strategic cooperation agreement with Wanfu Weikang. In February 2016, it was listed on the New Third Board.

The company's business can be categorized into the tumor product line, chronic disease product line, infectious product line, maternal and child product line, and IVD product line. Its business covers more than 30 provinces. Some main business of the tumor product line category includes lung cancer, colorectal cancer, breast cancer, solid tumor, thyroid carcinoma, and gynecological tumor. The application fields include early screening, incidental diagnosis, genetic and gene detection Treatment monitoring, and other areas of diagnosis.

## Funding rounds

- Series D, Jun 2, 2022, $15M — CAS Capital, Sanya Yazhouwan Venture Capital
- Series C, Jul 13, 2020, $17M — CAS Investment Management
- Series A, Jun 25, 2015 — Step Venture Capital

## Investors

- Step Venture Capital (https://capitalatlas.ai/funds/step-venture-capital) — Series A
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series C
- CAS Capital — Series D
- Sanya Yazhouwan Venture Capital — Series D